Pain and Therapy最新文献

{"title":"Vulvodynia and Chronic Vulvar Pain: Influencing Factors and Long-Term Success After Therapeutic Local Anesthesia (TLA).","authors":"Axel Gerhardt, Manuel Feisst, Thomas Strowitzki, Oliver Zivanovic, Stefan Weinschenk","doi":"10.1007/s40122-025-00725-7","DOIUrl":"10.1007/s40122-025-00725-7","url":null,"abstract":"<p><strong>Introduction: </strong>Vulvodynia is a debilitating sexual disorder with a high prevalence of 7-11%. In the study reported here, we analyzed long-term results from a prospective, non-controlled observational study to enhance our understanding of the success of therapeutic local anesthesia (TLA) and to investigate factors that predict a response or failure of therapy, with the overall aim to gain new insights into the complex medical condition of vulvodynia.</p><p><strong>Methods: </strong>A total of 45 patients diagnosed with severe chronic vulvodynia or chronic vulvar pain (Numeric Analog Scale [NAS] ≥ 6, median 7.9, duration ≥ 6 months, median 65.2 months) and previously treated with TLA were re-evaluated 4.5-13 years after therapy. Therapy response was defined as NAS ≤ 4 for at least 6 months.</p><p><strong>Results: </strong>Of the 45 patients originally diagnosed with vulvodynia, 38 were available for follow-up (32 of the original 36 responders, and 4 of the 9 non-responders). The average follow-up period was 7.9 years (95.2 months, range 55-156 months) after the end of therapy. All responders remained symptom-free, and two of the non-responders also became responders. Factors associated with non-response were: the number of physicians seen previously, lichen sclerosus, previous traumata, relapses of recurrent cystitis, corticoid therapy, and psychological factors, including depression, psychotropic drug intake, and psychotherapy. Body mass index (BMI) was lower in non-responders. The number of deliveries, cesarean sections, abortions, age, hormonal status, other medication intake, and gynecological surgeries had no impact on the results.</p><p><strong>Conclusion: </strong>The long-term success of TLA supports the hypothesis that neuralgia of one or more nerves of the pelvic floor is an important component in the development of vulvodynia. This study provides evidence for the long-term effectiveness of TLA in women with vulvodynia, as well as potential obstacles to healing. Despite limitations imposed by a monocentric, non-controlled observational design, the robustness of this investigation lies in the long observation period after treatment and the substantial percentage of patients for whom TLA was successful. The long-term results emphasize the necessity of a holistic approach integrating the view of vulvodynia as a peripheral neuro-functional disorder.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":"1025-1043"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland.","authors":"Caroline S Casey, Mari Pölkki, Elisa K Suvanen, Ilona Iso-Mustajärvi, Timo Purmonen, Essi J Peltonen, Camilla K Appel, Niraj J Patel, Lill-Brith Von Arx","doi":"10.1007/s40122-025-00719-5","DOIUrl":"10.1007/s40122-025-00719-5","url":null,"abstract":"<p><strong>Introduction: </strong>Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) were the first preventive migraine treatment group to target the underlying cause of migraine. This survey evaluated real-life experiences of adults with migraine in Finland before and after using their current subcutaneous CGRP mAb treatment.</p><p><strong>Methods: </strong>Adult users of a subcutaneous CGRP mAb for migraine prevention were recruited for an electronic cross-sectional survey by Finnish community pharmacies and Migraine Finland (a patient advocacy group) in 2023. The survey included questions regarding monthly migraine headache days, absenteeism, general disability, pain intensity, treatment patterns, and a validated Migraine-Specific Quality of Life (MSQoL) questionnaire.</p><p><strong>Results: </strong>The survey was completed by 383 users of subcutaneous CGRP mAb medication, of whom 78 (20.4%) were receiving galcanezumab. Users of galcanezumab, the latest CGRP mAb to be reimbursed in Finland, had more previous CGRP mAb treatment switches than users of other CGRP mAbs. Following any subcutaneous CGRP mAb use, changes were observed in the number of monthly migraine headache days (0-7 experienced by 17/379 participants [4.5%] with data before, versus 302/379 [79.7%] after using treatment; ≥ 12 experienced by 279/379 [73.6%] before, versus 34/379 [9.0%] after), monthly sick leave days (from 139/376 [37.0%] to 15/376 [4.0%] with ≥ 4 monthly sick leave days), overall ability to work or study (from 180/377 [47.7%] to 287/377 [76.1%] able to work or study full time) and average intensity of migraine pain (median [lower-upper quartile] from 8.0 [7.0-9.0] before to 6.0 [4.0-8.0] after). No differences were observed between total MSQoL scores for new (0-6 months CGRP mAb use) versus persistent (≥ 6 months use) users of any CGRP mAb.</p><p><strong>Conclusions: </strong>Patient experiences of using subcutaneous CGRP mAbs in Finland showed improvements in several migraine-related factors, supporting the potential for CGRP mAbs to improve the quality of life of adults with migraine.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":"1045-1061"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pain Control Paradigms: A Comparative Review of Anesthesia Techniques in Trigeminal Neuralgia Therapy.","authors":"Lan Lai, Keyue Xie","doi":"10.1007/s40122-025-00738-2","DOIUrl":"10.1007/s40122-025-00738-2","url":null,"abstract":"<p><p>This review summarizes the intraoperative anesthesia protocols for radiofrequency thermal coagulation in the treatment of trigeminal neuralgia, focusing on the advantages and disadvantages of two primary anesthesia approaches. The first approach involves the injection of local anesthetics, such as lidocaine, at the radiofrequency target, which can alleviate pain during the procedure but carries potential risks. The second approach discusses the efficacy of intravenous administration of propofol for pain control, highlighting the necessity for vigilant monitoring of vital signs during the procedure. This article aims to provide the latest evidence-based guidance for anesthesia protocol selection in clinical practice.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":"881-889"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal Therapies for the Treatment of Neuropathic Pain: The Role of Lidocaine Patches in Combination Therapy: A Narrative Review.","authors":"Srinivas Nalamachu, Theresa Mallick-Searle, Jeremy Adler, Elaine K Chan, Wendy Borgersen, Dmitri Lissin","doi":"10.1007/s40122-025-00733-7","DOIUrl":"10.1007/s40122-025-00733-7","url":null,"abstract":"<p><p>Neuropathic pain (NP) has a population presence of up to 10%. Both systemic agents and topical agents are recommended as first-line therapy for the treatment of NP but monotherapy provides adequate pain relief only in < 50% of the cases. This has created the need for multimodal combination therapy, a practice that is becoming more common. Combination therapy with multiple systemic agents has a risk for drug-drug interactions and adverse events (AEs), while add-on therapy with a topical agent such as lidocaine patches minimizes such risks. The focus of this review was to find if there is evidence from trials that combination therapy of the topical lidocaine patches with systemic agents will have better efficacy and/or less risk of AEs than the combination of two systemic agents. Since gabapentinoids are one of the most common systemic agents used in first-line NP therapy, the objective of this review was to summarize the safety and efficacy data and evaluate the benefit-risk ratio from three gabapentinoid combinations; gabapentinoid plus opioids, gabapentinoid plus antidepressants, and gabapentinoid plus topical lidocaine patches. Reviews of clinical trials of combinations of gabapentinoids plus other systemic agents (opioids or antidepressants) were associated with increased AEs and dropouts while improvement in analgesic efficacy was inconsistent. Clinical trials where the patients were provided topical lidocaine patches when their first treatment with a gabapentinoid was inadequate demonstrated improved analgesic efficacy with minimal additional AEs. This led to the conclusion that topical lidocaine patches-associated with minimal systemic adverse effects and proven benefits in various neuropathic pain (NP) conditions-can enhance the likelihood of achieving meaningful pain relief when used as adjuvant therapy for NP.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":"865-879"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four-Year Follow-Up from a Prospective, Multicenter Study of Percutaneous 60-Day Peripheral Nerve Stimulation for Chronic Low Back Pain.","authors":"Christopher A Gilmore, Timothy R Deer, Mehul J Desai, Sean Li, Michael J DePalma, Steven P Cohen, Brandon D Swan, Meredith J McGee, Joseph W Boggs","doi":"10.1007/s40122-025-00737-3","DOIUrl":"10.1007/s40122-025-00737-3","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic low back pain (LBP) is a leading cause of healthcare expenditure and long-term disability associated with complex treatment challenges and the need for progressively invasive interventions. Percutaneous 60-day Peripheral Nerve Stimulation (PNS) is a minimally invasive neurostimulation treatment that has shown efficacy for chronic LBP, providing sustained improvements through 1 year of follow-up after treatment. The present work explores the long-term clinical outcomes of Percutaneous 60-day PNS for chronic LBP approximately 4 years after initial treatment.</p><p><strong>Methods: </strong>Follow-up surveys were sent to participants from a prior prospective study who reported clinically meaningful reductions in pain, disability, or pain interference 12 months after Percutaneous 60-day PNS for LBP. The present long-term follow-up survey assessed current levels of LBP, disability, pain interference, and Patient Global Impression of Change (PGIC). Use of medications and other interventions for LBP treatment since completing Percutaneous 60-day PNS was also surveyed.</p><p><strong>Results: </strong>In total, 23 participants returned completed long-term follow-up surveys. A majority of survey respondents (65%, n = 15/23) reported sustained, clinically meaningful (≥ 30%) relief of back pain compared with baseline an average of 4.7 years after PNS treatment was initiated. On average, these long-term responders reported clinically substantial (≥ 50%) reductions in pain (average 63% reduction), as well as clinically meaningful improvements in disability and quality of life. Furthermore, 70% (n = 16/23) of survey respondents avoided progression to more costly, invasive, and/or destructive LBP pain interventions (i.e., radiofrequency ablation, neurostimulation implant, or lumbar surgery).</p><p><strong>Conclusions: </strong>Treatment with Percutaneous 60-day PNS provided clinically meaningful pain relief among a majority of surveyed participants an average of more than 4 years after the short-term treatment. These results demonstrate that Percutaneous 60-day PNS can provide durable outcomes that are often sustained for multiple (4+) years by patients with chronic axial LBP who subsequently avoid the need for more invasive treatment interventions.</p><p><strong>Clinical trial registration: </strong>The Clinicaltrials.gov registration number for the initial study is NCT03179202.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":"1103-1115"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-Rich Plasma for Treating Chronic Noncancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Fengfeng Wang, Fei Meng, Timmy Chi Wing Chan, Stanley Sau Ching Wong","doi":"10.1007/s40122-025-00751-5","DOIUrl":"https://doi.org/10.1007/s40122-025-00751-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Chronic noncancer pain represents a significant global health challenge, contributing to disability, lost productivity, diminished quality of life, and substantial socioeconomic burden. Platelet-rich plasma (PRP) has emerged as a promising therapeutic option for managing chronic pain. However, a comprehensive assessment of its efficacy and the evidence supporting its use remains limited. This study aimed to systematically evaluate the analgesic effectiveness of PRP compared with placebo or active drug treatments across a wide range of chronic noncancer pain conditions using a rigorous meta-analytic approach. The goal is to provide evidence-based insights to inform clinical decision-making and improve patient outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive literature search was conducted in the PubMed, Embase, MEDLINE, and Cochrane Library databases to identify randomized controlled trials (RCTs). Studies were screened according to predefined inclusion and exclusion criteria. A random-effects model was applied to account for heterogeneity among studies. The primary outcome, pain scores in patients with chronic noncancer pain, was assessed using the standardized mean difference (SMD). The risk of bias of the included studies was evaluated using the Revised Cochrane Risk-of-Bias Tool (RoB 2). The quality of evidence was rated by the Grade of Recommendations Assessment, Development, and Evaluation (GRADE) approach.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 691 RCTs were screened, and 56 studies (comprising 103 comparisons and 7142 patients) were eligible for analysis. PRP was associated with a statistically significant reduction in pain scores compared with both active drug treatments and placebo (SMD = -0.37, 95% confidence interval (CI) -0.59 to -0.15, p = 0.001). No significant differences were observed in pain scores for follow-up periods shorter than 3 months (SMD = 0.12, 95% CI -0.16 to 0.40, p &gt; 0.05). A statistically significant and moderate reduction in pain score was found for follow-up durations of at least 3 months (SMD = -0.69, 95% CI -0.98 to -0.40, p &lt; 0.001). Meta-analyses of subgroups revealed statistically significant and moderate pain reduction in favor of PRP versus active drug treatments for osteoarthritic knee pain (SMD = -0.59, 95% CI -1.01 to -0.17, p = 0.009) and rotator cuff tendinopathy/tear (SMD = -0.60, 95% CI -1.01 to -0.19, p = 0.01), but no significant differences for plantar fasciitis (SMD = 0.03, 95% CI -0.98 to 1.04, p &gt; 0.05). PRP was associated with moderate pain reduction when compared with corticosteroid (SMD = -0.53, 95% CI -0.98 to -0.08, p = 0.02) and hyaluronic acid injection (SMD = -0.55, 95% CI -0.89 to -0.21, p = 0.004).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;PRP injections appear to effectively reduce pain in various chronic noncancer pain conditions and show sup","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144187594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Posterior Quadratus Lumborum Block on Acute Pain Relief and Chronic Pain Prevention in Breast Cancer Surgery.","authors":"Min Wang, Shu-Jie Niu, Jin Wu, Yi-Wei Zhong, Zi-Yun Lu, Qun Fu, Bing-Bing Li","doi":"10.1007/s40122-025-00740-8","DOIUrl":"https://doi.org/10.1007/s40122-025-00740-8","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer surgery is a common surgical procedure often associated with acute and chronic postoperative pain. As part of multimodal analgesia, the erector spinae plane block (ESPB) has been shown to effectively alleviate pain after breast cancer surgery. This study is the first to apply the posterior quadratus lumborum block (posterior QLB) for perioperative analgesia in breast cancer surgery. The aim of this research was to evaluate whether ESPB and QLB2 can relieve acute and chronic pain following breast cancer surgery.</p><p><strong>Methods: </strong>A total of 120 female patients undergoing breast cancer surgery were randomly assigned to receive either ESPB, posterior QLB, or no intervention. All patients were administered sufentanil patient-controlled intravenous analgesia postoperatively. The primary outcome was the visual analog scale (VAS) pain scores recorded at 2, 6, 18, 24, and 48 h post-surgery under rest and motion conditions. Secondary outcomes included the incidence of moderate-to-severe pain within 24 and 48 h post-surgery, intraoperative fentanyl cumulative dosage, postoperative rescue analgesia, chronic pain incidence, recovery quality of life, and adverse events.</p><p><strong>Results: </strong>Compared to the group receiving conventional treatment (group C), the incidence of moderate-to-severe pain within 24 h post-surgery was significantly lower in both the group receiving ESPB (group E; 16.7% vs. 46.2%, P < 0.05) and the group receiving QLB (group Q; 20.5% vs. 46.2%, P < 0.05). Additionally, the proportion of patients requiring rescue analgesia was significantly reduced in both group E and group Q, compared to group C (group C vs. E vs. Q: 30.8% vs. 7.1% vs. 10.3%, P = 0.007; group C vs Q: 30.8% vs. 10.3%, P = 0.025; group C vs. E: 30.8% vs 7.1%, P = 0.006; group Q vs. E: 10.3% vs. 7.1%, P = 0.141). At 3 months post-surgery, group Q had a significantly lower incidence of chronic pain compared to both group C (19.5% vs. 71.8%, P < 0.05) and group E (19.5% vs. 57.1%, P < 0.05). No significant differences were observed between the groups in terms of VAS scores at 2, 6, 18, 24, or 48 h, intraoperative fentanyl consumption, postoperative nausea and vomiting, time to first mobilization, time to first oral intake, the length of hospital stay, or Quality of Recovery-15 Items (QoR-15) scores at 3 months post-surgery (all P > 0.05).</p><p><strong>Conclusion: </strong>Compared with conventional intravenous analgesia, the combination of ultrasound-guided ESPB and posterior QLB significantly reduces the incidence of moderate-to-severe pain and the need for rescue analgesia within 24 h post-surgery. Furthermore, a single posterior QLB significantly reduces the incidence of chronic pain at 3 months post-surgery in patients with breast cancer.</p><p><strong>Trial registration: </strong>Clinical trial number: ChiCTR2000041471.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable Shoulder Pain Relief and Avoidance of Surgery Up To 5 Years Following 60-Day PNS Treatment.","authors":"Kevin E Vorenkamp, Gemayel Lee, Denise D Lester, Chaitanya Konda, Steven P Cohen, Nate D Crosby, Joseph W Boggs","doi":"10.1007/s40122-025-00746-2","DOIUrl":"https://doi.org/10.1007/s40122-025-00746-2","url":null,"abstract":"<p><strong>Introduction: </strong>Shoulder pain can be a chronic, disabling condition resulting in major procedures like surgery that are invasive, costly, and pose significant risks to patients. Minimally invasive interventions that provide durable relief can improve outcomes while enabling patients to avoid accruing additional healthcare costs. The present survey study evaluated durability of pain relief in a real-world shoulder pain population following percutaneous 60-day peripheral nerve stimulation (PNS) treatment.</p><p><strong>Methods: </strong>A cross-sectional follow-up survey assessed follow-up outcomes among patients who received 60-day PNS for chronic shoulder pain. Outcomes included patient-reported percent pain relief, average and worst pain scores, and patient impression of change in quality of life, physical function, and sleep. Patients also reported other treatments and interventions used for their shoulder pain since the 60-day PNS treatment including changes in medication usage.</p><p><strong>Results: </strong>Among 489 survey participants (mean follow-up 21 months, range 6-60), 83% (405/489) reported no subsequent radiofrequency ablation, permanent implant, or surgery following 60-day PNS. Within this subset, 87% reported ongoing improvement in at least one domain at follow-up, including 71% who maintained ≥ 50% pain relief, and more than half who reported much or very much improved quality of life (61%), physical function (57%), or sleep (57%). Among those using PNS seeking to avoid surgery (n = 265), 81% reported no subsequent surgery, with 77% of those patients maintaining ≥ 50% pain relief. Outcomes were consistent across follow-up durations and shoulder pain etiologies.</p><p><strong>Conclusions: </strong>This real-world evidence demonstrates that a large majority of responders to 60-day PNS may experience durable shoulder pain relief and other improvements, with benefits demonstrated up to 5 years post treatment. The low rate of progression to subsequent interventions including surgery suggests potential for healthcare economic benefit, supporting 60-day PNS as both a clinically effective and potentially economically advantageous approach for appropriate patients.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Onset of Pain Relief with Crisugabalin in Patients with Diabetic Peripheral Neuropathic Pain: Findings from a Multicenter, Randomized, Double-Blind, Controlled Study.","authors":"Tianrong Pan, Jianhua Ma, Yukun Li, Kailiang Wang, Chengxia Jiang, Yawei Zhang, Jie Liu, Ruiqin Du, Wei Zhang, Fang Bian, Fang Zhang, Lijun Wang, Shuguang Pang, Tao Ning, Bangqiong Wang, Ya Li, Xiaohong Wu, Keqin Zhang, Xulei Tang, Honglin Hu, Xin Sun, Ping Li, Zhifeng Cheng, Jia Sun, Jing Yang, Yanjun Wang, Jialin Gao, Hong Mao, Fangqiong Li, Qin Huang, Yaming Li, Zhixin Peng, Xiaohui Guo","doi":"10.1007/s40122-025-00745-3","DOIUrl":"https://doi.org/10.1007/s40122-025-00745-3","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the efficacy and safety of Crisugabalin in patients with diabetic peripheral neuropathic pain (DPNP), with a focus on its rapid onset of action.</p><p><strong>Methods: </strong>All the analyses in this study were based on data from a phase 2/3 adaptive randomized clinical trial that enrolled 596 patients. Participants were categorized into four treatment groups according to the intervention received: Crisugabalin 40 mg/day, Crisugabalin 80 mg/day, placebo, and Pregabalin 300 mg/day. The primary endpoint was the change in the average daily pain score (ADPS) over a 13-week treatment period. Secondary endpoints included changes in the Numeric Rating Scale (NRS) and the daily sleep interference score (DSIS) during the first two weeks of treatment.</p><p><strong>Results: </strong>Both Crisugabalin treatment groups (40 mg/day and 80 mg/day) demonstrated statistically significant reductions in ADPS compared to the placebo group starting from week 1 and continuing through week 13 (P < 0.05). Significant differences in pain relief for the Pregabalin group were observed only from week 6. Improvements in NRS and DSIS scores were also noted in both Crisugabalin groups, with statistically significant enhancements evident as early as day 2 of administration. Safety assessments indicated that Crisugabalin was well-tolerated, with a low incidence of serious adverse events and no significant increase in dropout rates among participants.</p><p><strong>Conclusion: </strong>The findings suggest that Crisugabalin offers effective pain relief with an acceptable safety profile, highlighting its rapid onset in patients with DPNP.</p><p><strong>Clinical trial registration: </strong>Clinical trial registration number derived from our parent project, we have retained the original registration identifier: NCT04647773.</p>","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor regarding \"Effects of TTP-PECS Block Under Opioid-Sparing General Anesthesia on Postoperative Analgesia and Early Recovery Quality in Patients Undergoing Modified Radical Mastectomy\".","authors":"Zhi-Bin Huang, Dan-Feng Wang, Fu-Shan Xue","doi":"10.1007/s40122-025-00743-5","DOIUrl":"https://doi.org/10.1007/s40122-025-00743-5","url":null,"abstract":"","PeriodicalId":19908,"journal":{"name":"Pain and Therapy","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}